Why holding overnight is not as risky as traders think

The Ripple Effect of Shifting Medical Procedure Demand

Intuitive Surgical has become the centre of a healthcare demand debate after its shares fell sharply following its latest results. The company reported slower growth in US robot-assisted procedures and warned that insurance coverage, premiums and patient affordability could influence treatment timing. Many procedures performed with Intuitive Surgical’s da Vinci systems are not emergencies. Patients may postpone them when deductibles rise, slowing procedure growth, recurring instrument sales and servicing revenue. Winners Managed-care insurers Names: $UNH (UnitedHealth Group), $CI (The Cigna Group), $HUM (Humana) Why they may win: If patients delay expensive surgeries, insurers may pay fewer claims. Lower medical utilisation can improve medical cost ratios and support profitability. Lower enrolment or policy changes could offset this benefit, so these are possible relative winners rather than guaranteed beneficiaries. Chronic-care medical devices Names: $ABT (Abbott Laboratories), $DXCM (DexCom), $PODD (Insulet) Why they may win: These companies sell products used continuously to manage chronic conditions rather than products dependent on elective hospital procedures. Patients cannot easily postpone glucose monitoring or insulin delivery in the same way they might delay an operation, which could make these stocks more resilient. Defensive pharmaceutical companies Names: $LLY (Eli Lilly), $MRK (Merck), $ABBV (AbbVie) Why they may win: These companies generate most of their revenue from medicines rather than surgical procedures. Their earnings still face competition, patent risks and pricing pressure, but they are less directly tied to elective surgery volumes. Losers Surgical robotics and capital equipment Names: $ISRG (Intuitive Surgical), $SYK (Stryker) Why they may lose: Intuitive Surgical depends heavily on procedure growth. Fewer operations mean weaker demand for instruments, accessories and services used with each da Vinci procedure. Hospitals may also delay buying new systems if demand becomes less predictable. Stryker could face similar pressure through its Mako robotic platform and orthopaedic products. Elective procedure medical devices Names: $BSX (Boston Scientific), $MDT (Medtronic), $ZBH (Zimmer Biomet) Why they may lose: These companies sell products used in cardiovascular, orthopaedic and surgical procedures. Some treatments can be postponed from one quarter to another. Zimmer Biomet may be particularly sensitive because joint replacements are scheduled in advance, while softer hospital volumes could also affect Boston Scientific and Medtronic. Hospital operators Names: $HCA (HCA Healthcare), $THC (Tenet Healthcare), $UHS (Universal Health Services) Why they may lose: Hospitals could face lower elective surgery volumes while also seeing more uninsured or underinsured patients. That can reduce profitable procedures, weaken the payer mix and increase unpaid medical bills. Their earnings will help show whether the weakness is company-specific or part of a broader trend. What traders should watch Upcoming earnings across medical devices, hospitals and insurers will be crucial. Traders should listen for comments about elective procedures, hospital spending, deductibles, uninsured patients and medical utilisation. If more companies report the same pattern, this could become a healthcare-sector theme. If procedure volumes recover quickly, the sell-off in Intuitive Surgical and related names may prove excessive. #StockMarket #Trading #Investing #DayTrading #SwingTrading #HealthcareStocks #MedTech #MedicalDevices #Earnings #IntuitiveSurgical #SurgicalRobotics #HospitalStocks #HealthInsurance

Intraday noise can make good traders look stupid

A good trading decision can look completely wrong for several hours before the market proves it right. Intraday price action is full of false breaks, sharp reversals, algorithmic moves, headline reactions and emotional order flow. None of these automatically mean your analysis was poor. Many traders judge themselves by what happens immediately after entry. If price moves against them, they assume they made a mistake. If it moves in their favour, they assume they were right. But short-term movement is not always evidence. Sometimes it is simply volatility doing what volatility does. Why Good Trades Often Look Bad First A high-quality setup can still experience: • A sharp move against the position before reversing • A false breakout that triggers obvious stops A liquidity sweep above or below a key level • A temporary reaction to news or sentiment • A slow period before momentum arrives • A gap between the thesis and the market’s timing Judging a trade too early is dangerous. The market does not have to validate your idea immediately. Price may test your stop placement and patience before the trade develops. Noise Is Not New Information Noise is movement that does not materially change the setup. New information is something that genuinely weakens or invalidates the thesis. Traders who cannot tell the difference may exit strong positions too early, move stops impulsively or reverse at the worst moment. Before reacting, ask: • Has the technical structure actually broken? • Has the catalyst changed? • Has the company or sector received meaningful news? • Has the expected time horizon expired? • Has the original risk level been reached? • Or am I simply uncomfortable because price is moving against me? Discomfort is not always a signal. Sometimes it is only the emotional cost of holding through normal volatility. Good Trading Is About Process Professional trading is not about looking right every minute. It is about repeatable decisions based on defined risk. A good trade can lose, while a bad trade can win. One outcome does not prove the quality of the process. A strong process includes: • A clear reason for entering • A defined invalidation level • A position size that allows normal volatility • A realistic time horizon • A plan for taking profits • A willingness to accept uncertainty With these elements in place, intraday fluctuations become easier to tolerate. You stop treating every candle as a verdict on your ability. Match the Trade to the Timeframe A swing trade should not be managed like a scalp. A multi-day idea should not be abandoned because of one weak 15-minute candle. A reversal may look dramatic on a 5-minute chart but remain irrelevant on the daily chart. Return to the timeframe that produced the idea. Do not let a short-term emotional response overrule a longer-term plan without genuine evidence. Patience Is Not Blind Hope Patience does not mean holding forever or refusing to admit you are wrong. It means allowing the trade enough space and time to work while respecting the original invalidation point. Blind hope says, “It will come back.” Disciplined patience says, “The thesis remains valid, the risk is defined and the market has not reached the level that proves me wrong.” #StockMarket #Trading #Investing #DayTrading #SwingTrading #TradingPsychology #RiskManagement #PriceAction #MarketNoise #TradingDiscipline #TraderMindset #Patience

Abbott’s Resilient Medical Device Growth and Market Impact

Abbott Laboratories delivered a stronger-than-expected second quarter and raised its full-year profit outlook. Revenue reached $12.59 billion, adjusted earnings were $1.31 per share, and the company increased its 2026 adjusted EPS forecast to $5.45-$5.60 from $5.38-$5.58. $ABT rose around 12% as investors focused on resilient demand for cardiovascular devices, diabetes technology and cancer screening. Medical-device sales increased 9% to $5.85 billion, while diagnostics revenue reached $3.09 billion. The reported diagnostics increase included the Exact Sciences acquisition, while Cologuard generated mid-teens growth from new and repeat users. Winners Diversified medical-device companies Names: $ABT (Abbott Laboratories), $BSX (Boston Scientific), $SYK (Stryker), $MDT (Medtronic) Abbott is the direct winner because stronger results and higher guidance challenge fears that device demand is weakening. Boston Scientific, Stryker and Medtronic also gained after the update. These companies sell products used in cardiovascular treatment, surgery and chronic care. Resilient procedure demand could lift earnings expectations and medtech valuations. Diabetes and chronic-care technology Names: $PODD (Insulet), $TNDM (Tandem Diabetes Care), $EW (Edwards Lifesciences) Abbott said patients with diabetes, cardiovascular disease and cancer are less likely to postpone treatment. That supports Insulet and Tandem Diabetes Care, which sell insulin-delivery systems, and Edwards Lifesciences, which is exposed to structural-heart procedures. These businesses depend on recurring medical need rather than discretionary spending. Procedure-dependent surgical technology Names: $ISRG (Intuitive Surgical), $JNJ (Johnson and Johnson), $ZBH (Zimmer Biomet) Intuitive Surgical, Johnson and Johnson and Zimmer Biomet could benefit if Abbott improves procedure-related sentiment. Abbott’s cardiovascular growth suggests essential and semi-elective treatments may hold up better, supporting surgical robots, implants and hospital equipment. Losers Managed-care insurers Names: $UNH (UnitedHealth Group), $HUM (Humana), $ELV (Elevance Health), $CVS (CVS Health) Stronger procedure demand is not positive for every healthcare company. UnitedHealth, Humana, Elevance Health and CVS Health can face higher claims when patients continue using hospitals, diagnostics and specialist treatments. Resilient treatment volumes can pressure insurers’ medical-cost ratios. Continuous glucose-monitoring competitors Names: $DXCM (DexCom), $SENS (Senseonics Holdings) DexCom and Senseonics face greater competition as Abbott expands Libre technology, distribution and its product range. Abbott’s scale could create pricing pressure, raise customer-acquisition costs and make health-plan coverage harder to secure. Cancer-screening challengers Names: $GH (Guardant Health), $GRAL (GRAIL) Guardant Health and GRAIL may face a stronger competitor as Abbott builds a broader cancer-diagnostics platform around Cologuard. Abbott’s resources may make adoption, reimbursement and investor attention harder for smaller companies. #StockMarket #Trading #Investing #DayTrading #SwingTrading #Abbott #ABT #HealthcareStocks #MedTech #MedicalDevices #Diagnostics #CancerScreening #DiabetesTechnology #Earnings #HealthcareInvesting #LongIdeas #ShortIdeas #MarketNews

Why holding overnight is not as risky as traders think

Many traders believe every position must be closed before the session ends because holding overnight automatically creates unacceptable risk. The fear usually comes from price gaps, unexpected headlines, earnings surprises or changes in global markets while the trader is asleep. Those risks are real, but the conclusion is often exaggerated. Holding overnight is not automatically reckless. What matters is position size, setup quality, liquidity, event awareness and preparation for an adverse move. Overnight risk is easier to see An overnight gap is obvious because the market may open away from the previous close. Intraday risk feels less dramatic, although sudden reversals and breaking news can strike at any time. Closing everything before the bell may avoid some gap risk, but it can create other problems: • Taking weaker trades because of pressure to make money quickly • Overtrading because every position must work within a few hours • Using tight stops that are hit by normal market noise • Missing trends that need several sessions to develop Risk does not disappear when a position is closed before the market shuts. It simply changes form. Time can improve a good setup Strong trades do not always move immediately. A breakout may need time to attract volume. A trend may pause before continuing. Forcing every idea into a single day can lead to premature exits. Holding overnight can provide exposure to multi-day momentum, breakout continuation, sector rotation, post-earnings drift and wider market trends. The advantage is giving a well-researched setup enough time while keeping risk controlled. Position size matters more than the clock A large overnight position can be dangerous. A smaller position may be manageable. Traders often focus too much on the holding period and not enough on exposure. Before holding overnight, ask: • How much could the stock realistically gap against me? • Is earnings, economic data or company news due? • Is the stock liquid enough to exit without excessive slippage? • Is my position small enough to survive an abnormal move? • Would a gap damage my account or create only a planned loss? When the size is appropriate, an overnight move does not have to threaten the account. The position should already allow for a different opening price. Not every trade belongs overnight Earnings, regulatory decisions, court rulings, clinical trial results or major economic announcements can create unusually high uncertainty. Thinly traded stocks may also gap sharply because liquidity is limited. Avoid holding when: • The original reason for entering is no longer valid • A major binary event is approaching • The position is too large for the possible gap • Liquidity is poor • The trade has become a hope-based rescue attempt The decision should come from the setup, not hope or emotional attachment. The real skill is planned exposure Risk management is not about eliminating uncertainty. It is about choosing acceptable risks and limiting the damage when the market behaves unexpectedly. Holding overnight can reduce screen time, lower the urge to overtrade and allow stronger trends to develop. The goal is not unlimited overnight exposure. It is to stop treating every overnight position as automatically irresponsible. A carefully selected trade, held at the correct size, with no major event risk and a clear exit plan, may be less dangerous than several rushed intraday trades. #StockMarket #Trading #Investing #DayTrading #SwingTrading #OvernightTrading #TradingPsychology #RiskManagement #PositionSizing #TradingDiscipline #GapRisk #TradingStrategy

The BlackRock Hegemony and the Asset Management Divide

BlackRock reported adjusted earnings of $13.91 per share, while assets under management reached a record $15.34 trillion. Clients added $192 billion of net new money, with strong demand across iShares ETFs, bonds, private credit and infrastructure. Its operating margin rose to 45.9%, and management increased planned 2026 share repurchases to $2 billion. The results show that BlackRock is benefiting from rising markets, ETF adoption and demand for private assets. Why the story matters Its growth shows that investors are still allocating money across public and private markets, although smaller managers may struggle as more capital flows towards global platforms. Winners Large diversified asset managers Names: $BLK (BlackRock), $BX (Blackstone) Reason: BlackRock is the direct winner from record assets, strong inflows, higher margins and increased share repurchases. Blackstone may benefit as investors continue allocating money to large private-market platforms with global brands and broad product ranges. Alternative asset managers Names: $KKR (KKR), $ARES (Ares Management) BlackRock’s private-market inflows indicate that demand for private credit and infrastructure remains healthy. KKR and Ares could benefit if pension funds, insurers and wealthy investors continue increasing allocations outside public stocks and bonds. Borrowers are also using private lenders when bank financing is restricted. Market infrastructure companies Names: $NDAQ (Nasdaq), $CME (CME Group) Reason: More assets flowing into ETFs can support trading activity, market data, index licensing and risk-management demand. Nasdaq benefits from exchange services and index products. CME benefits from futures and options activity across multiple asset classes. Losers Traditional active managers Names: $TROW (T. Rowe Price), $JHG (Janus Henderson) Reason: The strength of BlackRock’s iShares business highlights the continuing shift towards lower-cost ETFs and passive funds. Traditional active managers may face fee pressure and weaker flows if investors prefer index products. They must deliver stronger performance or specialised strategies to justify higher charges. Mid-sized investment managers Names: $BEN (Franklin Resources), $VCTR (Victory Capital) Reason: BlackRock can invest heavily in technology, compliance and distribution while spreading those costs across a much larger asset base. Mid-sized firms may struggle to match its pricing, brand and product range, even while the wider industry grows. Private-credit competitors Names: $OWL (Blue Owl Capital), $APO (Apollo Global Management) Reason: Blue Owl and Apollo can benefit from growing private-credit demand, but BlackRock is becoming a stronger competitor. More competition may raise fundraising costs, make attractive loans harder to secure and force managers to offer better terms. Trading takeaway The bullish interpretation is that BlackRock’s quarter confirms healthy fund flows, strong ETF demand and continued expansion in private markets. The bearish interpretation is that more industry profits may be captured by a small number of financial giants. For traders, $BLK is the main stock to watch. The reaction in $BX, $KKR, $ARES, $TROW, $BEN, $OWL and $APO may show whether investors view these results as positive for the sector or as proof that BlackRock is becoming harder to compete against. #StockMarket #Trading #Investing #DayTrading #SwingTrading #BlackRock #BLK #AssetManagement #ETFs #WallStreet #FinancialStocks #PrivateCredit #PrivateMarkets #AlternativeInvestments #MarketNews #Earnings #FundFlows